LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial

Yann Vano, R.T. Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, Diane Pannier, Denis Maillet, Marine Gross‐Goupil, Christophe Tournigand, Brigitte Laguerre, Philippe Barthélémy, Florence Joly, Gwénaëlle Gravis, Stefano Caruso, C-M. Sun, Virginie Verkarre, Wolf H. Fridman, Jessica Zucman‐Rossi, Catherine Sautès‐Fridman, Stéphane Oudard